circle-image

Short

Trend Resistance

Uptrend Above: 24160

Bull Market Above: 24330
circle-image

Term

Trend Point Acts

Trend Point: 24140

My PCR: 0.91
384 Range 54

Bear Market Signal

circle-image

View

Trend Suport

Down Below: 24120

Bear Market Below: 24000
Short Term View Historic Data

Nifty View Tomorrow: Tuesday 30 Jun 2026

Day Close

23946
Day High

24120
Day Low

23924
Day Avg

23997
29 Jun 2026
5 SMA

23990
10 SMA

24006
20 SMA

23674
50 SMA

23846
200 SMA

24882
5 EMA

23966
10 EMA

23974
20 EMA

23800
50 EMA

23886
Tomorrow
Resist 2

24170
Resist 1

24060
Mid Point

23960
Suport 1

23860
Suport 2

23780
52W High

26373
52w Low

22182
52w Down

9.2%
52w Up

7.95%
Panic View
Resist 2

24390
Resist 1

24225
Mid Point

23980
Suport 1

23735
Suport 2

23610
5d High

24261
5d Low

23784
10d High

24261
10d Low

23784
Days High & Low 20d High

24261
20d Low

23070
50d High

24601
50d Low

23070
All Avg

23887
FFTH

24102
FTTL

23943
TTTH

24102
TTTL

23705
High & Low Avg TTFH

23977
TFFL

23580
High Avg

24060
Low Avg

23743
All Avg

23902
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 29 Jun 2026 23946 24120 23924 23990 24006 23674 23846 24882
2 25 Jun 2026 24056 24261 24039 24003 23973 23654 23851 24886
3 24 Jun 2026 24021 24090 23789 24026 23884 23646 23847 24889
4 23 Jun 2026 23824 24135 23784 24038 23803 23641 23848 24892
5 22 Jun 2026 24102 24168 24073 24071 23745 23651 23847 24895
Nifty Historic Data And Moving Avg

Go Back

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net...

Posted: 14 Jan 2025

Morepen Laboratories Limited Amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year The details of turnover and net worth of Medical Devices Business as on March 31, 2024, are mentioned below: b) Date on which the agreement for sale has been entered into Subject to receipt of requisite regulatory and membersapprovals, the Board of Directors of the company hasapproved the sale of the Medical Devices Business of the company to Morepen Medtech Limited, a subsidiary company, as going concern on slump sales basis today i.e.January 14, 2025, including authorising the directors/ officers of the Company to enter the Business TransferAgreement (BTA) and other related documents to give effect to the transaction. The BTA will be executed in due course and will be informed to the Stock Exchanges separately. c) Expected date of completion of sale/disposal The completion of the slump sale of the Medical Devices Business is expected to be completed on or before September 30, 2025, subject to receipt of requisite regulatory and other approvals and fulfilment of customary conditions precedent and in accordance with the provisions of the BTA. d) Consideration received from such sale/disposal The consideration for such slump sale will be derived on the basis of the report of the independent valuer in respect of Building and Plant & Machinery, net current assets, other non-current assets and liabilities as per the Balance Sheet as on effective date of transfer of Medical Devices Business and will also be in compliance with Rule 11 UAE of Income Tax Rules 1962. e) Brief details of buyers and whether any of the buyers belong to the promoter/ Morepen Medtech Limited, is a public company (subsidiary of Morepen Laboratories Limited), incorporated on January 8, 2025, to carry on the business of medical devices. Morepen Laboratories Limited CIN NO. L24231 HP1984PLC006028 Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com promoter group/ group companies. If yes, details thereof Yes, Morepen Medtech Limited has been incorporated as a subsidiary of the company, with an aggregate shareholding of 20% of the entities belonging to the promoters group/ relatives of promoter/ members of promoter group. f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arms length? Yes, the transaction qualifies as a related party transaction and is being conducted on an arms length basis. Furthermore, the company will obtain approval from themembers. g) Whether the sale, lease or disposal of the undertaking is outside the Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations. Yes, the transaction is outside the Scheme of Arrangement.In compliance with Regulation 37A of the SEBI Listing Regulations the Medical Devices Business being anundertaking in terms of the provisions of the Companies Act, 2013, the company will seek the approval of the members of the company. h) Additional disclosures in case of a slump sale i. name of the entity(ies) forming part of the slump sale amalgamation/ merger, details in brief such as, size, turnover etc. Seller: Morepen Laboratories Limited Audited financial details as of March 31, 2024: Particulars Turnover (? in Lakh) Percentage Net worth (? in Lakh) Percentage Other Pharmaceutical Business* 1,24,771.66 73.81% 74,363.57 89.12% Medical Devices Business 44,271.59 26.19% 9,078.52 10.88% Total 1,69,043.25 100.00% 83,442.09 100.00% *Consolidated basis. Buyer: Morepen Medtech Limited, a subsidiary of Morepen Laboratories Limited, as incorporated on January 8, 2025, with the paid-up capital of ? 10,00,000/- (Rupees Ten Lakh Only). ii. whether the transaction would fall within related party transactions? If yes, whether the same is done at arms length Refer point no. (f) above.

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.